HK1215673A1 - 個使用抗 抗體減少腦部澱粉蛋白質斑的方法 - Google Patents

個使用抗 抗體減少腦部澱粉蛋白質斑的方法

Info

Publication number
HK1215673A1
HK1215673A1 HK16103618.8A HK16103618A HK1215673A1 HK 1215673 A1 HK1215673 A1 HK 1215673A1 HK 16103618 A HK16103618 A HK 16103618A HK 1215673 A1 HK1215673 A1 HK 1215673A1
Authority
HK
Hong Kong
Prior art keywords
antibodies
amyloid plaques
brain amyloid
reducing brain
reducing
Prior art date
Application number
HK16103618.8A
Other languages
English (en)
Inventor
Thierry Bussiere
Paul H Weinreb
Thomas Engber
Kenneth Rhodes
Joseph Arndt
Fang Qian
Robert W Dunstan
Shailendra Patel
Jan Grimm
Marcel Maier
Original Assignee
Biogen Int Neuroscience Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Int Neuroscience Gmbh filed Critical Biogen Int Neuroscience Gmbh
Publication of HK1215673A1 publication Critical patent/HK1215673A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1018—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
HK16103618.8A 2012-12-07 2016-03-30 個使用抗 抗體減少腦部澱粉蛋白質斑的方法 HK1215673A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261734799P 2012-12-07 2012-12-07
US201361773794P 2013-03-06 2013-03-06
PCT/US2013/073700 WO2014089500A1 (en) 2012-12-07 2013-12-06 A METHOD OF REDUCING BRAIN AMYLOID PLAQUES USING ANTI-Aß ANTIBODIES

Publications (1)

Publication Number Publication Date
HK1215673A1 true HK1215673A1 (zh) 2016-09-09

Family

ID=50884049

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16103618.8A HK1215673A1 (zh) 2012-12-07 2016-03-30 個使用抗 抗體減少腦部澱粉蛋白質斑的方法

Country Status (13)

Country Link
US (1) US20150315267A1 (zh)
EP (1) EP2928494A4 (zh)
JP (1) JP2016501247A (zh)
KR (1) KR20150127570A (zh)
CN (1) CN105979962A (zh)
AU (1) AU2013354968A1 (zh)
BR (1) BR112015013312A2 (zh)
CA (1) CA2894178A1 (zh)
EA (1) EA201591019A1 (zh)
HK (1) HK1215673A1 (zh)
IL (1) IL239259A0 (zh)
MX (1) MX2015007147A (zh)
WO (1) WO2014089500A1 (zh)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL199534A (en) 2007-01-05 2013-01-31 Univ Zuerich An isolated human antibody capable of detecting a neoepitope in a disease-related protein, a polynucleotide encoding an antibody, a vector containing the polynucleotide, a host cell containing the polynucleotide or vector, a preparation containing the antibody and related methods and uses.
CN105616405B (zh) * 2014-11-05 2021-05-07 中国人民解放军第三军医大学第三附属医院 依达拉奉在制备用于预防和治疗脑淀粉样血管病的药物中的应用
MA41115A (fr) * 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
CA2989444A1 (en) * 2015-07-15 2017-01-19 GestVision, Inc. Device for detecting misfolded proteins and methods of use thereof
JP2018522891A (ja) * 2015-07-21 2018-08-16 バイオアークティック アーベー 凝集ペプチドを標的とする外傷性脳損傷の治療方法
GB2541003A (en) * 2015-08-05 2017-02-08 Kran Life Sciences Llp Neurodegenerative disorders
JP2019501115A (ja) 2015-10-28 2019-01-17 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 遺伝子治療のためのアデノ随伴ウイルスベクターのくも膜下腔内投与
US11542332B2 (en) 2016-03-26 2023-01-03 Bioatla, Inc. Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
US20200308259A1 (en) * 2016-06-07 2020-10-01 Biogen International Neuroscience Gmbh Methods for treating alzheimer's disease
TWI735600B (zh) 2016-07-01 2021-08-11 美商美國禮來大藥廠 抗－N3pGlu類澱粉β肽抗體及其用途
US10662226B2 (en) 2016-10-28 2020-05-26 The Regents of the University of Caiifomia Synthetic beta-amyloid peptides capable of forming stable antigenic oligomers
MX2020001855A (es) 2017-08-22 2020-08-13 Biogen Ma Inc Composiciones farmacéuticas que contienen anticuerpos anti-beta-amiloides.
CN112601550B (zh) 2018-05-30 2023-12-08 财团法人卫生研究院 抗-乙型淀粉样蛋白抗体及其用途
US20230030950A1 (en) * 2019-12-03 2023-02-02 The University Of Queensland Treatment of neurodegenerative diseases using ultrasound and amyloid-beta antibodies
WO2022020680A1 (en) 2020-07-23 2022-01-27 Othair Prothena Limited Anti-abeta antibodies
WO2023180811A2 (en) 2022-03-22 2023-09-28 Insightec Ltd. Monitoring tissue permeability during ultrasound procedures

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120017469A (ko) * 2007-01-05 2012-02-28 유니버시티 오브 취리히 질환 특이적 결합 분자 및 표적을 제공하는 방법
EP2321348A2 (en) * 2008-07-09 2011-05-18 University of Zürich Method of promoting neurogenesis
ITRM20120383A1 (it) * 2012-03-20 2013-09-21 Uni Degli Studi Di Milano B Icocca Metodo e kit per la rivelazione di anticorpi.

Also Published As

Publication number Publication date
BR112015013312A2 (pt) 2017-11-14
IL239259A0 (en) 2015-07-30
JP2016501247A (ja) 2016-01-18
AU2013354968A1 (en) 2015-07-16
US20150315267A1 (en) 2015-11-05
CN105979962A (zh) 2016-09-28
CA2894178A1 (en) 2014-06-12
KR20150127570A (ko) 2015-11-17
EP2928494A1 (en) 2015-10-14
MX2015007147A (es) 2016-07-26
EP2928494A4 (en) 2016-11-02
WO2014089500A1 (en) 2014-06-12
EA201591019A1 (ru) 2015-11-30

Similar Documents

Publication Publication Date Title
HK1215673A1 (zh) 個使用抗 抗體減少腦部澱粉蛋白質斑的方法
HK1251530A1 (zh) 單服容器及通過使用單服容器來生產飲料的工藝
HK1210121A1 (zh) 劑量容器和用於借助於劑量容器生產飲料的方法
IL237617A0 (en) Methods to increase brain functionality using 2-fucosyl-lactose
EP2672883A4 (en) DEVICES AND METHODS FOR MONITORING CEREBRAL HEMODYNAMIC STATES
HUE037048T2 (hu) Eljárások 4-cikloalkiloxibenzolszulfonamidok elõállítására
EP2737942A4 (en) METHOD FOR PRODUCING A FILTER HELP
SG2014009591A (en) Spin forming method
EP2760035A4 (en) METHOD FOR PRODUCING MAGNETIC TREES
AP3748A (en) Method of producing hydrocarbons
EP2821392A4 (en) PROCESS FOR THE PREPARATION OF ACRYLNITRILE
EP2832768A4 (en) PROCESS FOR THE PREPARATION OF POLYIMIDE
PL2931937T3 (pl) Sposób wytwarzania układów nanocząstek metali
EP2799870A4 (en) METHOD FOR PREVENTING BUBBLE ADSORPTION
EP2693202A4 (en) METHOD OF MANUFACTURING A DEVICE FOR REINFORCING AN OPTICAL ELECTRICAL FIELD
EP2682217A4 (en) METHOD FOR MANUFACTURING SLIDING ELEMENT
HUE038055T2 (hu) Eljárás szulforafán szintetizálására
SG11201403485VA (en) Method of Forming Boding Structure
EP2870182A4 (en) PROCESS FOR PRODUCING UREA ADSORBENT
IL238515A0 (en) A method for the preparation of alpha-galactosyl ceramide compounds
IL229552A0 (en) A method of applying pressure to a material
PL2852513T3 (pl) Sposób wytwarzania podzespołów
EP2891652A4 (en) ALICYCLIC EPOXY COMPOUND AND PROCESS FOR THE PREPARATION THEREOF
EP2821390A4 (en) PROCESS FOR THE PREPARATION OF ACRYLNITRILE
EP2821391A4 (en) PROCESS FOR THE PREPARATION OF ACRYLNITRILE